Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

How has the viral vector manufacturing market size evolved in recent years?

The market for viral vector manufacturing has seen substantial growth in the past few years. The industry, predicted to escalate from $6.93 billion in 2024 to $8.33 billion in 2025, will have an impressive compound annual growth rate (CAGR) of 20.1%. Factors fueling this rise in the historic period include an upsurge in the pipeline of gene therapies, triumphs and approvals in clinical studies, a surge in biopharmaceutical investment, and rising instances of genetic disorders.

What are the predictions for the viral vector manufacturing market size in the coming years?

The market for viral vector manufacturing is projected to experience remarkable growth in the coming years, reaching a value of $17.68 billion in 2029, with a compound annual growth rate (CAGR) of 20.7%. This expected growth during the forecast period is due to the increased use of viral vectors in oncology, global co-operation in gene therapy studies, the implementation of viral vectors in developing vaccines, ongoing clinical trials, and commercialization. Key trends for this timeframe include advanced technological adaptations in vector creation, the introduction of next-generation vectors, adherence to regulatory standards and compliance, collaborative endeavors and partnerships, and worldwide expansion of manufacturing infrastructures.

Get your viral vector manufacturing market report here!

https://www.thebusinessresearchcompany.com/report/viral-vector-manufacturing-global-market-report

What key factors are fueling the growth of the viral vector manufacturing market?

The surge in cancer and infectious diseases cases is projected to spur the expansion of the viral vector manufacturing market. Infectious disease is characterized by conditions caused by a virus or its poisonous byproduct that is transmitted to a susceptible host through interaction with an infected individual, creature, or object. Cancer encompasses a variety of conditions that occur when abnormal cells grow uncontrollably, breach their normal boundaries to invade neighboring organs, and metastasize to other body parts. Tumor antigens, which are proteins on cancer cells, are generated using viral vectors to prompt the body’s immune response against cancer. Viral vectors have been used as vaccines in pre-clinical and clinical studies for a variety of infectious diseases. For example, data from the Australian Institute of Health and Welfare, a governmental agency in Australia, showed an increase in cancer cases diagnosed in Australia, rising from 160,570 in 2022 to 164,694 in 2023. This indicates a remarkable annual increase and signifies the escalating prevalence of cancer in Australia. Additionally, the UK Health Security Agency reported, in August 2024, a sharp rise in measles cases in England, with 368 in 2023 compared to 53 in 2022. The West Midlands and London accounted for 44% and 33% of these cases, respectively. As a result, the rising prevalence of cancer and infectious diseases is fueling the expansion of the viral vector manufacturing market.

How is the global viral vector manufacturing market divided into key segments?

The viral vector manufacturing market covered in this report is segmented –

1) By Type: Adenoviral Vectors, Adeno-Associated Viral Vectors, Lentiviral Vectors, Retroviral Vectors, Other Types

2) By Disease: Cancer, Genetic Disorders, Infectious Diseases, Other Diseases

3) By Workflow: Upstream Processing, Downstream Processing

4) By Application: Gene And Cell Therapy Development, Vaccine Development, Biopharmaceutical And Pharmaceutical Discovery, Biomedical Research

5) By End-User: Research Organizations, Biotech And Pharmaceutical Companies, Others End Users

Subsegments:

1) By Adenoviral Vectors: Serotype 5, Serotype 2, Serotype 26

2) By Adeno-Associated Viral Vectors: AAV2, AAV5, AAV8, AAV9, Others

3) By Lentiviral Vectors: HIV-1-Based Lentiviral Vectors, SIV-Based Lentiviral Vectors, Others

4) By Retroviral Vectors: Moloney Murine Leukemia Virus (MoMLV), Gammaretroviral Vectors, Others

5) By Other Types: Sendai Viral Vectors, Vesicular Stomatitis Virus (VSV)-Based Vectors, Measles Virus Vectors, Others

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12398&type=smp

Who are the key firms paving the way for growth in the viral vector manufacturing market?

Major companies operating in the viral vector manufacturing market include Sanofi S.A., Thermo Fisher Scientific Inc., Merck Group, FUJIFILM Holdings Corporation, Lonza Group, Catalent Inc., Sartorius AG, Charles River Laboratories International Inc., AGC Biologics, Ultragenyx Pharmaceutical Inc., Novasep Holding SAS, Aldevron LLC, Oxford Biomedica plc, LakePharma Inc., Voyager Therapeutics Inc., Mustang Bio Inc., Regenxbio Inc., VGXI Inc., BioNTech IMFS GmbH, FinVector Oy, Vigene Biosciences Inc., Univercells Technologies, Sirion-Biotech GmbH, Cevec Pharmaceuticals GmbH, Batavia Biosciences BV.

Which trends are expected to transform the viral vector manufacturing market?

In the viral vector manufacturing market, product innovation is emerging as a vital trend. Leading firms in this sector are employing product advancements to maintain their market standing. For example, Merck KGaA, a science and technology firm based in Germany, debuted the VirusExpress 293 Adeno-Associated Virus (AAV) Production Platform in August 2022. This company is amongst the first Contract development and manufacturing organizations and creators of technology to provide a comprehensive viral vector production package, encapsulating AAV, Lentiviral, CDMO, CTO, and process development. This inventive platform enables biopharmaceutical companies to reduce both the cost and duration of process development, subsequently quickening the clinical manufacturing timeframe.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12398

What regions are contributing significantly to the growth of the viral vector manufacturing market?

North America was the largest region in the viral vector manufacturing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the viral vector manufacturing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Browse Through More Similar Reports By The Business Research Company:

Thrust Vector Control Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/thrust-vector-control-global-market-report

Recombinant DNA Technology Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/recombinant-dna-technology-global-market-report

Viral Vectors And Plasmid DNA Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/viral-vectors-and-plasmid-dna-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: